The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.

PHASE3RecruitingINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

November 3, 2016

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Type 1 Diabetes MellitusDiabetic RetinopathyDiabetic Nephropathies
Interventions
DRUG

Fenofibrate

145 mg tablet of fenofibrate administered once daily for 36 months.

DRUG

Inert lactose placebo

Insert lactose tablet matching active tablet administered once daily for 36 months.

Trial Locations (24)

1051

RECRUITING

Auckland Diabetes Centre, Auckland

2010

RECRUITING

Garvan Institute of Medical Research, Darlinghurst

2032

RECRUITING

Prince of Wales Hospital, Randwick

2050

RECRUITING

Royal Prince Alfred Hospital, Camperdown

2065

RECRUITING

Royal North Shore Hospital, Saint Leonards

2139

RECRUITING

Concord Repatriation General Hospital, Concord

2170

RECRUITING

Retina Associates - South West Retina, Liverpool

2291

RECRUITING

Hunter Diabetes Centre, Merewether

2605

RECRUITING

Canberra Hospital, Garran

3004

RECRUITING

Baker Heart and Diabetes Institute, Melbourne

3021

RECRUITING

Sunshine Hospital, St Albans

3050

RECRUITING

The Royal Melbourne Hospital, Parkville

3065

RECRUITING

St Vincent's Hospital Melbourne, Melbourne

3081

RECRUITING

Heidelberg Repatriation Hospital, Heidelberg

3220

RECRUITING

University Hospital Geelong, Geelong

4101

RECRUITING

Mater Adult Hospital, South Brisbane

4102

RECRUITING

Princess Alexandra Hospital, Woolloongabba

4870

RECRUITING

Cairns Hospital, Cairns

5000

RECRUITING

Royal Adelaide Hospital, Adelaide

5046

RECRUITING

Southern Adelaide Diabetes and Endocrine Services, Oaklands Park

6160

RECRUITING

Fremantle Hospital, Fremantle

8011

RECRUITING

Christchurch Hospital, Christchurch

Unknown

RECRUITING

Prince of Wales Hospital, Shatin

BT12 6BA

RECRUITING

Belfast Health and Social Care Trust, Belfast

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Health and Medical Research Council, Australia

OTHER

collaborator

Juvenile Diabetes Research Foundation Australia

UNKNOWN

collaborator

Mylan Pharmaceuticals Inc

INDUSTRY

lead

University of Sydney

OTHER

NCT01320345 - The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye. | Biotech Hunter | Biotech Hunter